At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
In this issue of MIMS Cardiology Supplement, we bring you clinical updates related to combating hypercholesterolaemia, highlighting the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering low-density lipoprotein-cholesterol levels.
Home blood pressure monitoring (HBPM) is increasingly being recognized as an accurate adjunct to clinic blood pressure measurement for the diagnosis and management of hypertension. We discussed the HOPE Asia Network’s recently published consensus recommendations on HBPM with lead author, Prof. Sungha Park.
Click here to view the interview video with one of the authors - Professor Sungha Park
In an effort to better understand hypertension subtypes – including morning and white-coat hypertension – in Asian patients, the HOPE Asia Network has initiated the Asia BP@Home study across 12 countries and regions. We discussed the study’s design and objectives with lead investigator, Prof. Kazuomi Kario.
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
At a cardiology conference held in Hilton Kuala Lumpur, senior consultant cardiologist Dato’ Sri Dr Azhari Rosman spoke on the importance of non–high-density lipoprotein cholesterol (non–HDL-C) and combination therapy as a novel approach in the management of atherogenic dyslipidemia (AD).
Through a cardiology webcast hosted by Pfizer, Dr Jeyamalar Rajadurai, Dr Salim Virani and Dr Pamela Morris shared their insights into the importance of primary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.